Actelion - Company Information

Marketed Products

Trade Name	Generic Name	Indication	First Approved	Sales Q1 08
Tracleer®	bosentan	Pulmonary arterial hypertension	FDA 11/01	CHF 287.6 m
Ventavis®	iloprost	Pulmonary arterial hypertension	FDA 12/04	CHF 17.4 m
Zavesca®	miglustat	Mild to moderate Gaucher disease type 1	EMEA 11/02	CHF 9.7 m

Clinical Development Pipeline

Phase Product/
Compound Indication Study Results expected
IV Bosentan Combination bosentan & sildenafil in PAH COMPASS -2
n/a
IV Iloprost Pulmonary Arterial Hypertension (improved Delivery system)
n/a
n/a
IV Miglustat GD1 patients switched from ERT to miglustat MAINTENANCE
n/a
III Actelion -1 Pulmonary Arterial Hypertension SERAPHIN
n/a
III Almorexant Sleep disorders RESTORA
n/a
III Bosentan Idiopathic Pulmonary Fibrosis BUILD-3 H2 2009
III Clazosentan Vasospasm as consequence of subarachnoid hemorrhage (SAH) CONSCIOUS-2 H2 2009
II CRTH2 antagonist
Allergy
n/a
n/a
II Miglustat Cystic Fibrosis
n/a
H2 2008
II PGI2 agonist Pulmonary Arterial Hypertension
n/a
n/a
II Renin inhibitor Cardiovascular
n/a
n/a
I S1P1 agonist Immunology
n/a
2008